{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:40:01Z","timestamp":1785559201558,"version":"3.56.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kroner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cystic fibrosis (CF) is a monogenetic disease caused by an impairment of the cystic fibrosis transmembrane conductance regulator (CFTR). CF affects multiple organs and is associated with acute and chronic inflammation. In 2020, Elexacaftor\u2013Tezacaftor\u2013Ivacaftor (ETI) was approved to enhance and restore the remaining CFTR functionality. This study investigates cellular innate immunity, with a focus on neutrophil activation and phenotype, comparing healthy volunteers with patients with CF before (T1, n = 13) and after six months (T2, n = 11) of ETI treatment. ETI treatment reduced sweat chloride (T1: 95 mmol\/l (83|108) vs. T2: 32 mmol\/l (25|62), p &amp;lt; 0.01, median, first|third quartile) and significantly improved pulmonal function (FEV<jats:sub>1<\/jats:sub> T1: 2.66 l (1.92|3.04) vs. T2: 3.69 l (3.00|4.03), p &amp;lt; 0.01). Moreover, there was a significant decrease in the biomarker human epididymis protein 4 (T1: 6.2 ng\/ml (4.6|6.3) vs. T2: 3.0 ng\/ml (2.2|3.7), p &amp;lt; 0.01) and a small but significant decrease in matrix metallopeptidase 9 (T1: 45.5 ng\/ml (32.5|140.1) vs. T2: 28.2 ng\/ml (18.2|33.6), p &amp;lt; 0.05). Neutrophil phenotype (CD10, CD11b, CD62L, and CD66b) and function (radical oxygen species generation, chemotactic and phagocytic activity) remained largely unaffected by ETI treatment. Likewise, monocyte phenotype and markers of platelet activation were similar at T1 and T2. In summary, the present study confirmed a positive impact on patients with CF after ETI treatment. However, neither beneficial nor harmful effects of ETI treatment on cellular innate immunity could be detected, possibly due to the study population consisting of patients with well-controlled CF.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1180282","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T01:29:59Z","timestamp":1688088599000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor\u2013Tezacaftor\u2013Ivacaftor treatment"],"prefix":"10.3389","volume":"14","author":[{"given":"Hanna","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Melina","family":"H\u00f6pfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wohlgemuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane Leonie","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam Omar Khalaf","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Stukan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"M\u00fcnnich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"H\u00fcsken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Sebastian","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Elias Paul","family":"Stratmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Karl","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorit","family":"Fabricius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian Felix Nepomuk","family":"Bode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Huber-Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Alexander Christian","family":"Messerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"MBoC"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.2570460","article-title":"Identification of the cystic fibrosis gene: genetic analysis","volume":"245","author":"Kerem","year":"1989","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2005-0146OC","article-title":"Abnormalities in the pulmonary innate immune system in cystic fibrosis","volume":"34","author":"Moraes","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(20)80582-1","article-title":"The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. determination of functional half-lives on transfected cells","volume":"268","author":"Lukacs","year":"1993","journal-title":"J Biol Chem"},{"key":"B7","unstructured":"Cystic fibrosis foundation patient registry: 2021 annual data report"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00082-2019","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Taylor-Cousar","year":"2019","journal-title":"ERJ Open Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013Tezacaftor\u2013Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01233-7","article-title":"Elexacaftor\/Ivacaftor\/Tezacaftor: first approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B11","unstructured":"EPAR - product information"},{"key":"B12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00005-011-0113-6","article-title":"The cystic fibrosis neutrophil: a specialized yet potentially defective cell","volume":"59","author":"Hayes","year":"2011","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129635","article-title":"Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation","volume":"130","author":"Ortiz-Mu\u00f1oz","year":"2020","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041699","article-title":"Ion and water transport in neutrophil granulocytes and its impairment during sepsis","volume":"22","author":"Messerer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0907658","article-title":"The role of chloride anion and CFTR in killing of pseudomonas aeruginosa by normal and CF neutrophils","volume":"83","author":"Painter","year":"2008","journal-title":"J Leukoc Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.4.9704134","article-title":"Circulating adhesion molecules in cystic fibrosis","volume":"157","author":"De Rose","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.56.1.62","article-title":"Directed neutrophil migration to IL-8 is increased in cystic fibrosis: a study of the effect of erythromycin","volume":"56","author":"Brennan","year":"2001","journal-title":"Thorax"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000295791","article-title":"In cystic fibrosis homozygotes and heterozygotes, neutrophil apoptosis is delayed and modulated by diamide or roscovitine: evidence for an innate neutrophil disturbance","volume":"2","author":"Moriceau","year":"2010","journal-title":"J Innate Immun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2202096","DOI":"10.1183\/13993003.02096-2022","article-title":"Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis","volume":"61","author":"Dhote","year":"2023","journal-title":"Eur Respir J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1012310","article-title":"Specific circulating neutrophils subsets are present in clinically stable adults with cystic fibrosis and are further modulated by pulmonary exacerbations","volume":"13","author":"Martin","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.642867","article-title":"Activation of neutrophil granulocytes by platelet-activating factor is impaired during experimental sepsis","volume":"12","author":"Hug","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.571992","article-title":"Animal-free human whole blood sepsis model to study changes in innate immunity","volume":"11","author":"Messerer","year":"2020","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00252","article-title":"Roles, actions, and therapeutic potential of specialized pro-resolving lipid mediators for the treatment of inflammation in cystic fibrosis","volume":"10","author":"Recchiuti","year":"2019","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI57990","article-title":"A subset of neutrophils in human systemic inflammation inhibits T cell responses through mac-1","volume":"122","author":"Pillay","year":"2012","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5389-0","article-title":"Early PREdiction of sepsis using leukocyte surface biomarkers: the ExPRES-sepsis cohort study","volume":"44","author":"Shankar-Hari","year":"2018","journal-title":"Intensive Care Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.12.012","article-title":"Increased platelet activation occurs in cystic fibrosis patients and correlates to clinical status","volume":"162","author":"Lindberg","year":"2018","journal-title":"Thromb Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nri3399","article-title":"Neutrophil recruitment and function in health and inflammation","volume":"13","author":"Kolaczkowska","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1159\/000350215","article-title":"Neutrophils in the innate immunity conundrum of cystic fibrosis: a CFTR-related matter","volume":"5","author":"Witko-Sarsat","year":"2013","journal-title":"J Innate Immun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2200725","DOI":"10.1183\/13993003.00725-2022","article-title":"Elexacaftor-Tezacaftor-Ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis","volume":"61","author":"Cavinato","year":"2023","journal-title":"Eur Respir J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"B32","unstructured":"DhingraN\n          WHO guidelines on drawing blood: best practices in phlebotomy2010"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cells11203297","article-title":"Modulation of neutrophil activity by soluble complement cleavage products\u2013an in-depth analysis","volume":"11","author":"Wohlgemuth","year":"2022","journal-title":"Cells"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111504","article-title":"Simultaneous measurement of changes in neutrophil granulocyte membrane potential, intracellular pH, and cell size by multiparametric flow cytometry","volume":"9","author":"Stratmann","year":"2021","journal-title":"Biomedicines"},{"key":"B35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000514885","article-title":"Interleukin 8 elicits rapid physiological changes in neutrophils that are altered by inflammatory conditions","volume":"13","author":"Bernhard","year":"2021","journal-title":"J Innate Immun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2052356","DOI":"10.1155\/2018\/2052356","article-title":"Complement C5a alters the membrane potential of neutrophils during hemorrhagic shock","volume":"2018","author":"Messerer","year":"2018","journal-title":"Mediators Inflammation"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3TA0315-082R","article-title":"Platelet-neutrophil complex formation\u2013a detailed in vitro analysis of murine and human blood samples","volume":"99","author":"Mauler","year":"2016","journal-title":"J Leukocyte Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117172","article-title":"A novel exon in the cystic fibrosis transmembrane conductance regulator gene activated by the nonsense mutation E92X in airway epithelial cells of patients with cystic fibrosis","volume":"93","author":"Will","year":"1994","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00112-021-01397-1","article-title":"6 monate zulassung von kaftrio\u00ae in deutschland \u2013 erste erfahrungen aus dem wahren leben\u201d von menschen mit CF","author":"Thomassen","year":"2022","journal-title":"Monatsschr Kinderheilkd"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.04.006","article-title":"Human epididymis protein 4: a novel serum inflammatory biomarker in cystic fibrosis","volume":"150","author":"Nagy","year":"2016","journal-title":"Chest"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.08.013","article-title":"Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment","volume":"18","author":"Nagy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/bi060490t","article-title":"CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis","volume":"45","author":"Painter","year":"2006","journal-title":"Biochemistry"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/19.19.5417","article-title":"Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin","volume":"19","author":"Yoshimura","year":"1991","journal-title":"Nucl Acids Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2102861","DOI":"10.1183\/13993003.02861-2021","article-title":"Cystic fibrosis macrophage function and clinical outcomes after elexacaftor\/tezacaftor\/ivacaftor","volume":"61","author":"Zhang","year":"2023","journal-title":"Eur Respir J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1182\/blood-2014-02-555268","article-title":"A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy","volume":"124","author":"Pohl","year":"2014","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23712","article-title":"CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy","volume":"52","author":"Guerra","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jcf.2015.02.010","article-title":"Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor","volume":"15","author":"Bratcher","year":"2016","journal-title":"J Cystic Fibrosis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00461.2017","article-title":"Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill pseudomonas aeruginosa","volume":"314","author":"Barnaby","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"17066","DOI":"10.1038\/s41598-018-35151-7","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"eLife"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202106-1426OC","article-title":"Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis","volume":"205","author":"Gabillard-Lefort","year":"2022","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1180282\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T01:30:08Z","timestamp":1688088608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1180282\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2023.1180282"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1180282","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"article-number":"1180282"}}